AOL

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, ...
Seeking Alpha

Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer

Viatris (NASDAQ:VTRS) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic product targeting Venofer marketed by Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) ...
Morningstar

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity Viatris Chief R&D Officer Philippe Martin said, ...
Benzinga.com

Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

Amphastar Pharmaceuticals, Inc. AMPH, a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, ...
KTLA

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity PITTSBURGH, Aug. 11, 2025 /PRNewswire/ -- Viatris ...